- Home
- CPBI vs CUE Comparison
CPBI vs CUE Comparison
Compare CPBI & CUE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CPBI | CUE |
|---|---|---|
| Founded | 2023 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 66.8M | 49.6M |
| IPO Year | N/A | 2018 |
Fundamental Metrics
Financial Performance| Metric | CPBI | CUE |
|---|---|---|
| Price | $16.27 | $0.54 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $3.00 |
| AVG Volume (30 Days) | 4.9K | ★ 361.2K |
| Earning Date | 01-01-0001 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 7.32 | N/A |
| EPS | ★ 0.96 | N/A |
| Revenue | ★ $19,961,000.00 | $7,100,000.00 |
| Revenue This Year | N/A | $36.58 |
| Revenue Next Year | N/A | $32.10 |
| P/E Ratio | $16.97 | ★ N/A |
| Revenue Growth | ★ 9.30 | N/A |
| 52 Week Low | $13.00 | $0.53 |
| 52 Week High | $16.71 | $1.75 |
Technical Indicators
Market Signals| Indicator | CPBI | CUE |
|---|---|---|
| Relative Strength Index (RSI) | 60.99 | 34.41 |
| Support Level | $15.56 | $0.55 |
| Resistance Level | $16.17 | $0.66 |
| Average True Range (ATR) | 0.12 | 0.05 |
| MACD | 0.05 | -0.00 |
| Stochastic Oscillator | 98.76 | 13.24 |
Price Performance
Historical ComparisonAbout CPBI Central Plains Bancshares Inc.
Central Plains Bancshares Inc operates as the bank holding company for Home Federal Savings and Loan Association of Grand Island that provides mortgage, consumer, commercial real estate, and commercial loans, The bank business consists mainly of accepting deposits from the general public and investing those deposits, together with funds generated from operations, in one- to four-family residential mortgage loans secured by properties located in primary market area, as well as commercial real estate loans.
About CUE Cue Biopharma Inc.
Cue Biopharma Inc is a clinical-stage biopharmaceutical company. It is developing a novel and proprietary class of biologics drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its objective is to provide patients suffering from cancer and autoimmune diseases with dramatically improved therapeutic outcomes through the platform of biologic drug product candidates. The other products under pipeline are CUE-101 as a Monotherapy, CUE-101 + Pembrolizumab, CUE-102, CUE-103, and others.